AKRO Akero Therapeutics
- 19.710
- -0.370-1.84%
- 19.710
- 0.0000.00%
Akero Therapeutics News
Akero Therapeutics(AKRO.US) Officer Sells US$100.75K in Common Stock
$Akero Therapeutics(AKRO.US)$ Officer Young Jonathan sold 5,000 shares of common stock on May 1, 2024 at an average price of $20.1499 for a total value of $100.75K.Source: Announcement What is stateme
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
PDF Version SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients
Express News | B of A Securities Reinstates Neutral on Akero Therapeutics, Announces $30 Price Target
Akero Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 44.51% B of A Securities → $30 Reinstates → Neutral 03/05/2024 102.31% UBS $39 → $42 Maintains
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Akero Therapeutics(AKRO.US) Officer Sells US$121.91K in Common Stock
$Akero Therapeutics(AKRO.US)$ Officer Young Jonathan sold 5,000 shares of Common Stock on Apr 1, 2024 at an average price of $24.3826 for a total value of $121.91K.Source: Announcement What is stateme
Ademi LLP Investigates Claims of Securities Fraud Against Akero Therapeutics, Inc.
MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero may have
Form 144 | Akero Therapeutics(AKRO.US) Officer Proposes to Sell 379.2K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Akero Therapeutics(AKRO.US)$ Officer Jonathan Young intends to sell 15,000 shares of its common stock on Apr 1, with a total market value of approximately $379.2K. S
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
Inventiva Phase 2 Study for MASH Drug Meets Primary Endpoint
Madrigal's Stock Surges as FDA Approves First Drug for Liver Disease MASH
By Eleanor Laise 'Silent' disease affects an estimated 5% of U.S. adults Madrigal Pharmaceuticals Inc.'s stock jumped 25% premarket on Friday after the company scored the first Food and Drug Adminis
Madrigal Climbs Amid Hopes for New NASH Drug; B. Riley Upgrades
Madrigal Pharmaceuticals Gets First FDA Approval for Drug Targeting Liver Disease MASH
By Eleanor Laise 'Silent' disease affects an estimated 5% of U.S. adults Madrigal Pharmaceuticals Inc. on Thursday received the first Food and Drug Administration approval for a drug designed to tre
Madrigal and Liver Drug Developers Fall Ahead of FDA Decision on NASH Therapy
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Liver Drug Developers Outperform as U.S. Awaits First NASH Drug
Ionis Stock Jumps as MASH Drug Succeeds in Mid-stage Trial
Akero Therapeutics Raises $367 Million From Share Offering
Akero Therapeutics (AKRO) said late Friday it has closed its public offering of shares, raising almost $367 million. The company said it sold 12.65 million shares at $29 apiece in the offering, includ
Press Release: Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWS
Analysis
Price Target
No Data
